#### FISCAL IMPACT OF PROPOSED LEGISLATION



Legislative Fiscal Office 83<sup>rd</sup> Oregon Legislative Assembly 2025 Regular Session

Prepared by: MaryMichelle Sosne

Reviewed by: Amanda Beitel, John Borden, Emily Coates

Date: April 2, 2025

Bill Title: Relating to restrictions on 340B covered entities.

Government Unit(s) Affected: Board of Pharmacy, Department of Consumer and Business Services, Judicial

Department

### **Summary of Fiscal Impact**

Costs related to the measure are indeterminate at this time - see explanatory analysis.

# **Summary of Revenue Impact**

Revenue related to the measure is indeterminate at this time - see explanatory analysis.

## **Measure Description**

The measure prohibits manufacturers or their representatives from interfering with the acquisition, delivery, or dispensation of 340B drugs by pharmacies that have contracts with covered entities to provide these drugs on their behalf. It also prevents manufacturers from requiring covered entities to submit claims or utilization data as a condition for acquiring, delivering, or dispensing 340B drugs through specified pharmacies. The measure grants the Oregon Board of Pharmacy (OBOP) the authority to impose a civil penalty of up to \$5,000, per day on manufacturers who violate these provisions.

# **Fiscal Analysis**

The fiscal impact of the measure is indeterminate. Currently, OBOP has 1,140 registered manufacturers, however, manufacturers are not required to disclose whether they provide 340B drugs when registering with OBOP. As a result, OBOP cannot estimate the potential increase in revenue from enforcing the measure. If the implementation significantly increases OBOP's workload, additional staff may be required.

The measure has a minimal impact on the Oregon Judicial Department and no fiscal impact on the Department of Consumer and Business Services.

## **Relevant Dates**

The measure takes effect on January 1, 2026.

Measure: SB 533